CEP-14513
CEP-14513 is an ALK inhibitor with an IC50 of 4 nM. CEP-14513 also inhibits insulin receptor, VEGFR2, TIE2 and DLK kinases, but does not inhibit MET, IKKβ, or CDK1/2/5. CEP-14513 induces cancer cell apoptosis. CEP-14513 is applicable to research related to non-small cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, and diffuse large B-cell lymphoma.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 856693-04-4
- Fòrmula: C34H36N6O3
- Peso molecular:576.70
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas VEGFR
MoreVer todos los productos específicos de isoformas MAP3K
More
Actividad biológica
|
VEGFR2 |
Tie2 |
MAP3K12/DLK |
CEP-14513 inhibits the proliferation of ALK-mutant cell lines, with a cellular IC50 value of 10-30 nM[1].
CEP-14513 potently inhibits purified NPM-ALK fusion kinase with an IC50 < 5 nM, while it shows no inhibitory activity against CDK1/CDK2/CDK5, MET and IKKβ[2].
CEP-14513 inhibits tyrosine phosphorylation in NPM-ALK-transformed cells, with an IC50 < 30 nM[2].
CEP-14513 selectively inhibits proliferation and colony formation of NPM-ALK-transformed cells, and induces their apoptosis, while exhibits extremely low activity against ALK-negative K562 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 856693-04-4
-
Peso molecular 576.70
-
Fòrmula C34H36N6O3
-
SMILES
O=C(OC1=CC=C2C(=C1)C=3C(=C4C(C5=CN(N=C5CC4)C)=C6C(=O)NCC63)N2CC(C)C)NCC7=CC=C(C=C7)N(C)C
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1].
Puig de la Bellacasa R, et al. ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Transl Lung Cancer Res. 2013 Apr;2(2):72-86.
[Content Brief]
[2]. Gunby RH, et al. Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy. Anticancer Agents Med Chem. 2007;7(6):594-611. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz